Risk of tuberculosis with anti‐tumor necrosis factor‐α therapy: substantially higher number of patients at risk in <scp>A</scp>sia

Abstract

Higher numbers of patients are at risk of developing TB with anti-TNF-α therapy in Asia compared with Western Europe and North America. The relative lower risk of TB with etanercept may be particularly relevant for Asia, an endemic area for TB.